Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)

This non-randomized, single-group assignment trial (n=50) aims to investigate the glutamatergic mechanisms of psychosis and target engagement using ketamine hydrochloride in healthy volunteers.

The study, conducted by the New York State Psychiatric Institute, involves 2 identical ketamine-induced pharmacoBOLD (phBOLD) sessions at least 7 days apart. Ketamine doses will be assigned in successive 10 subject cohorts, starting at 0.08 mg/kg, with subsequent doses adjusted to determine the lowest dose that still produces a robust phBOLD response.

Participants will undergo MRI scans and clinical assessments, with the primary outcome measures being the phBOLD response to ketamine and changes in the Brief Psychiatric Rating Scale (BPRS) scores. The study aims to develop phBOLD as a biomarker for glutamatergic treatment development and explore mechanisms of psychosis. It started on January 1, 2021, and is estimated to be completed by February 1, 2025.

Topic Healthy Subjects
Compound Ketamine
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

New York State Psychiatric Institute
The New York State Psychiatric Institute (NYSPI), established in 1895, was one of the first institutions in the United States to integrate teaching, research and therapeutic approaches to the care of patients with mental illnesses.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.